Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Non-malignant285 active trials7 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Clinical trials
1,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | terminated | Phase 1 / Phase 2 |
| 38 |
| Hoffmann-La RocheINDUSTRY |
| 6 |
| Dec 20, 2024 |
| clinicaltrials |
| NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | recruiting | Early Phase 1 | 30 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT03649438 | 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | no longer available | — | — | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06699472 | A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib | recruiting | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00002730 | Chemotherapy in Treating Children With Neuroblastoma | completed | Phase 1 | — | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05826158 | 18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma | recruiting | N/A | 25 | Rigshospitalet, DenmarkOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT00695279 | Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products | completed | — | 41 | St. Jude Children's Research HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT02601937 | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | completed | Phase 1 | 109 | Epizyme, Inc.INDUSTRY | 9 | Oct 3, 2024 | clinicaltrials |
| NCT06029218 | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy(P1V2) | recruiting | N/A | 106 | Centre Antoine LacassagneOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04753658 | Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib | terminated | — | 15 | PfizerINDUSTRY | 6 | Sep 23, 2024 | clinicaltrials |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | terminated | Phase 1 | 74 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06438614 | A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma(NICE) | completed | Phase 2 | 47 | Fundació Sant Joan de DéuOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06574698 | Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma | recruiting | — | 64 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06564272 | A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma | recruiting | Phase 2 | 30 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT01464606 | International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry | active not recruiting | N/A | 156 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06182410 | Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT00601003 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | completed | Phase 2 | 112 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00867568 | TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma | completed | Phase 1 | 18 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | completed | Phase 1 | 21 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01109238 | A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma | completed | — | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01355679 | Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma | completed | N/A | 16 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | terminated | Phase 1 / Phase 2 | 8 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01505608 | Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma | terminated | Phase 1 / Phase 2 | 14 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01802567 | Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer | completed | N/A | 52 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | completed | Phase 2 | 140 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT02630043 | Trial of Tolcapone With Oxaliplatin for Neuroblastoma | terminated | Phase 1 | 5 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06335745 | PediCARE Health Equity Intervention in High-Risk Neuroblastoma | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Aug 5, 2024 | clinicaltrials |
| NCT04129151 | Palbociclib + Ganitumab In Ewing Sarcoma | terminated | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06526897 | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | not yet recruiting | N/A | 1,582 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06502210 | Identification of New Gene Spliceosomes in Neuroblastoma | unknown | — | 20 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT06499636 | In Vitro Models From Pediatric Brain Tumors(PBTS23) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | terminated | Phase 1 | 50 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04315883 | Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | terminated | — | 3 | Nemours Children's ClinicOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05245123 | Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families(PsyRareCare) | completed | — | 100 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT06451302 | Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study | active not recruiting | N/A | 100 | Yizhuo ZhangOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT03517280 | Nutritional Status in Neuroblastoma in Sao Paolo, Brazil | completed | — | 17 | Columbia UniversityOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT02383498 | QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | completed | Phase 2 | 24 | NantCell, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT06296732 | Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification(ANLAP-R) | recruiting | — | 200 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT02107963 | A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 16, 2024 | clinicaltrials |
| NCT02641314 | Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma(METRO-NB2012) | completed | Phase 2 | 18 | University of CologneOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 27, 2024source: clinicaltrials